News

The Translational Research Institute for Pain in Later Life, a New York City-based center to help older adults prevent and manage pain, has been awarded a five-year, $5 million renewal grant from the National Institute on Aging.

Non-white communities had significantly less access to opioid medications commonly prescribed for moderate to severe pain than white communities over the decade beginning in 2011, according to a study by Weill Cornell Medicine researchers.

Drs. Steven Josefowicz, Ekta Khurana and Kristen Pleil were among 400 early-career scientists and engineers to receive the Presidential Early Career Award for Scientists and Engineers.

The overwhelming majority of those in New York City who obtained a naloxone kit to counteract opioid overdose had a high need for the drug, according to a new study by Weill Cornell Medicine investigators and the New York City Department of Health and Mental Hygiene.

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies.

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

Beneficial gut microbes and the body work together to fine-tune fat metabolism and cholesterol levels, according to a new preclinical study.

Dr. Jim Castellanos, an instructor in anesthesiology, has been selected as a 2024 Hanna H. Gray Fellow by the Howard Hughes Medical Institute.

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery.

The hormone estrogen regulates binge drinking in females, causing them to “pregame”—consume large quantities of alcohol in the first 30 minutes after it’s offered, according to a preclinical study led by scientists at Weill Cornell Medicine. 

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer’s disease by latching on to them, forming a sort of external stomach and releasing digestive enzymes into the space, according to a preclinical study by Weill Cornell Medicine investigators.

After years of research, Dr. Gary Gibson’s work has culminated in a nationwide clinical trial evaluating an entirely new treatment approach for slowing Alzheimer’s progression.

A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.

Reinforcement Learning, an artificial intelligence approach, has the potential to guide physicians in designing sequential treatment strategies for better patient outcomes but requires significant improvements before it can be applied in clinical settings, finds a new study by Weill Cornell Medicine researchers.

Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

A new study by Weill Cornell Medicine investigators has found that free fatty acids, including an omega-3 fatty acid called DHA, can reduce the amount of glutamate uptake by diminishing the sodium ion gradient that powers the transporters.

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

Weill Cornell Medicine and Champions Oncology signed a licensing agreement allowing Champions Oncology to distribute and commercialize Weill Cornell Medicine’s extensive bank of hematological PDX models

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.